Alithea Genomics, a Lausanne, Switzerland-based company which specializes in RNA sequencing and transcriptomics, raised CHF 2.8M in Seed Extension funding.
The round was led by Novalis Biotech Acceleration fund and included new investor TechU Ventures alongside existing investors.
The company intends to use the funds to continue commercialization and expand manufacturing capacity of its RNA sequencing products, advance the development of new technologies, and establish a subsidiary in the United States.
Led by CEO Riccardo Dainese, Alithea Genomics is committed to developing solutions that simplify and streamline the generation of “big RNA data”. Its BRB-seq technologies and kits enable researchers to discover novel biomarkers and essential data needed to develop new drugs at a fraction of the traditional cost and time.
Commenting on the news, Riccardo Dainese said: “As a company, we have made significant progress in a short period of time, but we are far from finished, so I’d like to thank Novalis Biotech and existing investors for the continued support, and welcome TechU Ventures, who bring to the table a different perspective, particularly as we expand into the US.”
FinSMEs
14/03/2024